Nothing like a little drama to end your summer, right? Market volatility dragged biotech down this week, and then lifted it back up—at least as of Friday morning. But if you’re confused by the tumult and looking for some distractions, we’ve... Read more »
[Updated and corrected 8/27/15, 7:28pm, see below.] The new race to fight cholesterol is on. For the second time in a month, the U.S. Food and Drug Administration has approved a drug for people with dangerous levels of cholesterol... Read more »
For the first time ever, Yahoo brought its Mobile Developer Conference to New York—talking up its plans to more firmly embrace mobile and trying to coax more app developers to work with its software and services.
The two-day conference started with... Read more »
The demand for small-business lending services is an ever-growing part of the financial world. New York-based Biz2Credit is positioning itself to keep riding this trend.
Like others in this sector, co-founder and CEO Rohit Arora says Biz2Credit exists to address gaps... Read more »
If Syndax Pharmaceuticals’ latest financing is any indication, the Waltham, MA-based firm looks to have another shot at an initial public offering in mind.
Syndax has closed a $80 million Series C financing round from a large swath of “crossover” investors... Read more »
[UPDATED 8/26/15. See below.] Taking in its first-ever outside funding, CB Insights is growing its ranks, working on its software, and kicking off a new service called CB Insights for Sales.
New York-based venture data firm CB Insights... Read more »
Versant Ventures is about to launch its latest biotech incubator. And it’s picked the emerging New York life sciences scene as its home.
This morning, Versant, the San Francisco Bay Area VC firm, is announcing the formation of what’s being called... Read more »
[Corrected 8/24/15, 12:40 pm. See below.] The booming field of digital health means different things to different people. Even the president of StartUp Health, a New York-based firm that wants to help build 1,000 digital health startups—yes, literally—acknowledges... Read more »
The top story in biotech this week was the FDA’s approval of the first drug meant to boost women’s sex drive. The controversial flibanserin (Addyi) had been rejected in the past by the agency, and even post-approval faces questions about... Read more »